Related Experiment Video
Updated: Jun 8, 2026
05:45
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model
1Laboratory of Pneumology, Katholieke Universiteit Leuven and University Hospitals Leuven, Leuven, Belgium. wim.wuyts@uzleuven.be
Experimental Lung Research
|September 30, 2010
Summary
Azithromycin shows promise in treating pulmonary fibrosis. This study found the antibiotic reduced lung scarring and improved lung function in a mouse model, suggesting a potential role in idiopathic pulmonary fibrosis treatment.
Area of Science:
- Pulmonary Medicine
- Immunology
- Pharmacology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with no effective treatments.
- Its pathogenesis involves continuous lung injury, inflammation, and scarring, leading to respiratory failure.
- Current understanding of IPF pathogenesis remains incomplete.
Purpose of the Study:
- To investigate the therapeutic effect of azithromycin on bleomycin-induced pulmonary fibrosis in mice.
- To explore azithromycin's impact on immune responses in the context of lung fibrosis.
Main Methods:
- Pulmonary fibrosis was induced in C57BL/6 mice using bleomycin.
- Azithromycin was administered to a subset of bleomycin-treated mice.
- Bronchoalveolar lavage, histology, and pulmonary function tests were conducted at specific time points.
Main Results:
- Bleomycin induced significant lung fibrosis and restrictive lung function.
- Alterations in innate immune cells (neutrophils, macrophages) and adaptive immune cytokines (T(H)2, T(H)17, Treg) were observed.
- Azithromycin treatment markedly reduced lung fibrosis and improved pulmonary function.
Conclusions:
- Azithromycin demonstrated a beneficial effect in a mouse model of pulmonary fibrosis.
- The mechanism may involve modulation of both innate and adaptive immune responses.
- These findings suggest azithromycin could be a potential therapeutic agent for IPF.
